These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 28656517

  • 1. Treatment of Hyperkalemia in Heart Failure.
    DeFilippis EM, Desai AS.
    Curr Heart Fail Rep; 2017 Aug; 14(4):266-274. PubMed ID: 28656517
    [Abstract] [Full Text] [Related]

  • 2. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A, Mandreoli M.
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [Abstract] [Full Text] [Related]

  • 3. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA, Gales MA.
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [Abstract] [Full Text] [Related]

  • 4. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS, Bhagat AA, Anker SD, Butler J.
    Handb Exp Pharmacol; 2017 Jun; 243():537-560. PubMed ID: 28382468
    [Abstract] [Full Text] [Related]

  • 5. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [Abstract] [Full Text] [Related]

  • 6. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.
    Hundemer GL, Sood MM.
    Pharmacol Res; 2021 Oct; 172():105835. PubMed ID: 34438065
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis.
    Abuelazm M, Badr A, Turkmani M, Amin MA, Amin AM, Aboutaleb A, Gowaily I, Soliman Y, Abdelazeem B.
    ESC Heart Fail; 2024 Feb; 11(1):28-43. PubMed ID: 38012095
    [Abstract] [Full Text] [Related]

  • 11. Hyperkalemia in heart failure: Foe or friend?
    Rakisheva A, Marketou M, Klimenko A, Troyanova-Shchutskaia T, Vardas P.
    Clin Cardiol; 2020 Jul; 43(7):666-675. PubMed ID: 32445223
    [Abstract] [Full Text] [Related]

  • 12. Hyperkalemia Associated with Renin-Angiotensin-Aldosterone System Inhibition in Patients with Heart Failure; Underexplored and Overrated?
    Koratala A, Aboud H, Kazory A.
    Nephron; 2018 Jul; 138(3):220-221. PubMed ID: 29176327
    [No Abstract] [Full Text] [Related]

  • 13. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J, Caballero R, Delpón E.
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.